Advertisement
Advertisement
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
15.88
USDSponsored
+0.17
+1.08%
Aug 07, 15:59 UTC -4
Closed
After-Market
16.00
+0.12
+0.78%
GLUE Earnings Reports
Positive Surprise Ratio
GLUE beat 14 of 21 last estimates.
67%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$5.63M
/-$0.40
Implied change from Q2 26 (Revenue/ EPS)
-37.19%
/-6.98%
Implied change from Q3 25 (Revenue/ EPS)
-55.87%
/+21.21%
Monte Rosa Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, GLUE reported earnings of -0.43 USD per share (EPS) for Q2 26, missing the estimate of -0.39 USD, resulting in a -9.58% surprise. Revenue reached 8.97 million, compared to an expected 5.63 million, with a 59.21% difference. The market reacted with a +0.64% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 5.63 million USD, implying an decrease of -6.98% EPS, and decrease of -37.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
FAQ
What were Monte Rosa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Monte Rosa Therapeutics, Inc. Common Stock reported EPS of -$0.43, missing estimates by -9.58%, and revenue of $8.97M, 59.21% above expectations.
How did the market react to Monte Rosa Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.64%, changed from $15.61 before the earnings release to $15.71 the day after.
When is Monte Rosa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Monte Rosa Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Monte Rosa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $5.63M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement